Clinical Trial Update: Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS) [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 immunotherapy trial for high-risk Ductal carcinoma in situ is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ductal Carcinoma in Situ

Snippet

Sponsor: Laura Esserman | Conditions: Carcinoma, Intraductal, Noninfiltrating | EARLY_Phase 1 | Status: ACTIVE_NOT_RECRUITING